Pharmacogenomics, genetic tests, and patent-based incentives

Area of Science:

• Pharmacogenomics
• Biotechnology
• Health Economics

Background:

• Pharmacogenomics utilizes genetic information to personalize drug therapy, aiming to enhance medication safety and effectiveness.
• Genetic testing offers a pathway to optimize patient-drug matching, revolutionizing medical treatment paradigms.

Purpose of the Study:

• To evaluate the efficacy of patent-based incentives in stimulating the development of pharmacogenomic tests.
• To determine the optimal balance between public and private sector investment in pharmacogenomic research and development (R&D).

Main Methods:

• Analysis of patent-based incentives for genetic test creation.
• Economic evaluation of public versus private sector R&D in pharmacogenomics.
• Assessment of factors influencing private returns and costs for genetic tests.

Main Results:

• Strong incentives exist for developing genetic tests linked to new drug development and predicting adverse reactions.
• Weaker incentives are observed for genetic tests associated with existing drugs, potentially impacting drug sales and market differentiation.
• Public sector R&D is recommended for tests with low private returns or high private costs, such as those with low adoption rates or broad applicability.

Conclusions:

• Patent incentives are most effective for pharmacogenomic tests developed alongside new drugs.
• Targeted public R&D investment is essential for genetic tests that may be underprovided by the private market.
• Strategic R&D investment is key to maximizing the societal benefits of pharmacogenomics.